Pharmaceutical Technology

MAY 11, 2023

Of the 50 leading companies in the pharma industry, U.S. To further understand GlobalData's analysis on Internet of Things (IoT) Market Size, Share, Trends Analysis, and Segment Forecast 2021-2026 buy the report here. Centers for Disease Control and Prevention had the most mentions of internet of things in Q1 2023.

Media 52

Media Pharma Competition Marketing 52

European Pharmaceutical Review

FEBRUARY 12, 2024

Liam Dunne, MSD Biotech Site Lead, explains that the site operates at the forefront of science and technology with 15,000L-scale, repeatable, robust manufacturing processes to produce highly sensitive monoclonal antibodies (mAbs). How does it do this? Since 2021, Liam Dunne is the site head of MSD Biotech in Dublin.

Manufacturing 98

Manufacturing Medicine Leads Patients 98

World of DTC Marketing

FEBRUARY 22, 2021

billion by 2026. This has abuse potential written all over it and could lead to more dangerous health problems. One of the most common complaints people have is “lack of energy” Consumers have turned to energy drinks which was valued at $53.01 billion in 2018, and is expected to grow at a CAGR of 7.20% to reach $86.01

Pharma 181

Pharma Doctors Side effects Prescription 181

Pharmaceutical Technology

MAY 29, 2023

It provides forward-looking analysis of the market including market sizing up to 2026, segmentation by application, potential growth opportunities, and competitive pr Buy the report here.

Pharmaceutical 52

Pharmaceutical Marketing Competition Medicine 52

PM360

SEPTEMBER 21, 2023

The MFPs will be announced publicly in September 2024 and go into effect on January 1, 2026. CMS negotiation may lead to additional savings for beneficiaries and for the Medicare program. Some stakeholders have expressed concern that negotiation could lead to a reduction in drug innovation.

Manufacturing 111

Manufacturing Marketing Competition Physicians 111

Pharmaceutical Technology

MARCH 10, 2023

At Sandoz, we are determined to continue leading the way in driving access to these critical medicines. Work on the new biologics production plant is expected to commence this year, and complete operations are scheduled to begin in late 2026.

Food and Drug Administration 52

Food and Drug Administration Networking Medicine Food 52

European Pharmaceutical Review

FEBRUARY 8, 2023

It is set to retain its market-leading position as the most lucrative CD19 CAR-T agent in NHL, with annual sales reaching $1.7 Breyanzi is approved for DLBCL, and a label expansion is anticipated for expansions into marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL) in 2026 and 2028, respectively.

Marketing 98

Marketing Sales Physicians Patients 98

European Pharmaceutical Review

MAY 11, 2023

At the same time its 1.875 percent Notes due 2026 will begin trading under ‘RVTY 26.’ Revvity’s Q1 earnings webcast is scheduled on 11 May 2023 at 08:00 ET. Register here. The Company will trade under its new name and the stock ticker symbol ‘RVTY’ at market open on 16 May 2023.

Government 96

Government Prospecting Media Marketing 96

Pharmaceutical Technology

JULY 26, 2022

NPC is a rare inherited disease resulting from the body's inability to conduct intracellular transport of cholesterol and other lipids, leading to the abnormal accumulation of these substances in various bodily tissues, including brain tissue.

Marketing 122

Marketing Transportation Leads Patients 122

Clarivate

MAY 14, 2024

While initially developed to help regulate blood sugar levels, they have also been found to promote appetite suppression, leading to weight loss in patients. What’s leading to the boom in development of semaglutide biosimilars? Per recent Clarivate estimates, the therapeutic market for these drugs is valued at approximately $1.7

Manufacturing 52

Manufacturing Marketing Leads Medicine 52

European Pharmaceutical Review

AUGUST 22, 2024

billion” last year, two key players in the market, namely Novo Nordisk and Eli Lilly and Company, are set to lead the market, the analytics company forecasts: “collectively capturing 94 percent of the total 2030 GLP-1R sales”. Eli Lilly shared that production of the medicines will commence at the Lebanon site towards the end of 2026.

Medicine 59

Medicine Marketing Manufacturing Sales 59

pharmaphorum

AUGUST 5, 2022

The structure of the agreement on this drug is a little different, with Innovent developing the drug but Sanofi taking the lead on commercialisation, with the Chinese biotech standing to receive up to €60 million in milestones plus royalties.

Side effects 89

Side effects Marketing Pharma Medicine 89

Pharmaceutical Technology

JULY 28, 2022

Construction work started in Q2 2022 and is expected to be completed in Q1 2026. The project aims to support the growing pipeline position, advanced manufacturing process and Industry-leading investigational RNAi medicines which continue to expand rapidly. Yeosu Dilute Nitric Acid Manufacturing Plant – $135m.

Pharmaceutical 52

Pharmaceutical Manufacturing Medicine Leads 52

pharmaphorum

NOVEMBER 6, 2022

Worldwide, RSV infections lead to more than three million hospitalisations and almost 60,000 deaths in children under five years of age every year, with around half of fatalities in infants less than six months. AZ and Sanofi say they hope to launch the antibody next autumn, in time for the 2023/24 RSV season.

Marketing 64

Marketing Sales Manufacturing Pharma 64

pharmaphorum

JULY 26, 2022

That will fund operations until 2026, beyond the readout of phase 3 trials including the BROADWAY study of obicetrapib in adults with heterozygous familial hypercholesterolaemia (HeFH) and/or established atherosclerotic cardiovascular disease (ASCVD) who can’t control LDL cholesterol on statin drugs alone.

Side effects 52

Side effects Safety Pharma Patients 52

pharmaphorum

JANUARY 18, 2023

That pressure can lead to diagnostic errors, with a 2018 study suggesting that there are 40 million errors involving imaging worldwide every year. billion.

Medical 59

Medical Pharma Media Sales 59

Infuse Medical

JULY 4, 2024

Regular maintenance helps prevent device malfunctions that could lead to incorrect diagnoses, treatment delays, or patient harm. Their efficiency in healthcare professionals leads to better patient care and operational efficiency. It leads to faster and more effective skill development. billion by 2026.

Training 52

Training Medical Healthcare Healthcare 52

Clarivate

AUGUST 7, 2024

The pricing estimates are not guaranteed, leading to potential unexpected expenses. The reliance on AWP and MAC, which often exceed actual pharmacy costs, may lead to higher expenses for plan sponsors. OptumRx Cost Advantage (launched in April, 2023) A flexible, pass-through model using average ingredient costs.

Retail 59

Retail Marketing Competition Biopharma 59

Spotio

JUNE 6, 2022

Sales Prospecting Statistics The way companies prospect for leads is changing. HubSpot] 9 in 10 companies use 2+ lead enrichment tools to learn more about prospects. Invest in a toolset that allows you to quickly build profiles and find accurate lead data in your target market. Well, the data suggests otherwise.

Sales 111

Sales Prospecting B2B Sales Leads 111

Clarivate

OCTOBER 25, 2023

The initial list, which takes effect in 2026, has the potential to roil formularies since it includes a mix of high-volume, preferred brands and a group of high-cost specialty drugs for autoimmune conditions (psoriasis) and cancer. Part D cannot cover drugs covered under Part A or Part B , forcing them to be addressed separately.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

pharmaphorum

JANUARY 10, 2023

Research by Treasure Data , a market leading enterprise customer data platform (CDP), shows that HCPs are increasingly turning to digital to research scientific information, new medications, and brands. billion by 2026, according to research by the Business Research Company. Capturing market share. billion in 2021 to $9.23

Marketing 98

Marketing Pharma Healthcare Healthcare 98

pharmaphorum

OCTOBER 18, 2022

Eli Lilly has agreed to buy hearing loss gene therapy developer Akouos in a deal that could value the company at around $610 million – if its lead candidate progresses as hoped in the clinic. The buyout – for $12.50 Lilly said there’s no guarantee the CVRs will be paid, and that the payments will shrink by $0.42

Medicine 52

Medicine FDA Patients Pharma 52

Pharmaceutical Technology

MARCH 7, 2023

HRT, or systemic estrogen therapy, is also a leading medication to treat perimenopausal symptoms. With an estimated completion date of May 2026, the study strives to utilise the endocrine biology of perimenopause to explain the behavioural and neurobiological features of depression in perimenopausal women.

Medical 52

Medical Management Leads Pharmaceutical 52

Spotio

APRIL 21, 2023

Recent research shows that the hardware as a service market (HaaS) should reach $300+ billion in 2026. The tips, tricks, and best practices below will help your team excel at both, leading to more revenue for your company. Simple: tell your reps to contact X amount of leads a day. Do you sell POS systems? Who are they?

Sales 52

Sales Prospecting Leads Sales pitches 52

Pharmaceutical Technology

APRIL 28, 2023

Key among them has been the extension of Syngene’s research collaboration with leading biotech company Amgen Inc. until 2026. Another notable contract that the company recently signed was with the leading Animal Health company, Zoetis. For more details, visit www.syngeneintl.com HQ ADDRESS: Syngene International Ltd.

Manufacturing 52

Manufacturing Government Pharmaceutical Leads 52

European Pharmaceutical Review

MARCH 9, 2023

There are emerging trends in oncology, with new chemical entities (NCEs) and antibody-drug conjugates (ADC) leading to increased demand for HPAPI manufacturing capabilities. References Global high potency active pharmaceutical ingredient (HPAPI) market report 2022: A $34+ billion market in 2026 – long-term forecast to 2031.

Safety 98

Safety Pharmacology Training Manufacturing 98

pharmaphorum

JANUARY 29, 2023

While global health spending per capita was about US$1,100 in 2018, this is forecast to rise to US$1,700 by 2026, outpacing GDP growth over the same period. Secondly, pressure on healthcare spending is leading to greater consolidation.

Healthcare 91

Healthcare Healthcare Manufacturing Marketing 91

Spotio

NOVEMBER 14, 2023

Some AI tools can emulate human behaviors and interact with prospects and customers in authentic ways, leading to more sales, revenue, and success for users. Like nurturing leads.) If you don’t, your reps will waste time talking to leads who will never convert into paying customers. Why Is It Important to Use AI in Sales?

Sales 52

Sales Prospecting Sales pitches Sales process 52

Clarivate

SEPTEMBER 5, 2024

Starting in 2026, the first ten self-administered Part D drugs in the law’s cross hairs will receive price cuts of 38%-79%. With the passage of the Inflation Reduction Act (IRA), the United States government gained the ability to directly negotiate drug prices with manufacturers.

Insurance 52

Insurance Marketing Manufacturing Prescription 52

PM360

APRIL 7, 2023

However, Medicare will only be able to negotiate prices for 10 Part D drugs in 2026, another 15 Part D drugs in 2027, another 15 Part D and Part B drugs in 2028, and another 20 Part D and Part B drugs for 2029 and subsequent years. It’s amazing we still separate the drug costs from overall healthcare costs,” Sontupe says.

Marketing 52

Marketing Pharma Manufacturing Healthcare 52

pharmaphorum

JULY 5, 2022

Prior to this, he founded the industry-leading publication, pharmaphorum, in 2009, which also provides broader content communications and marketing services to enable more effective customer engagement.

Patients 95

Patients Medicine Marketing Recruitment 95

Pharmaceutical Technology

JANUARY 10, 2023

There is a general decline in the major brands across the DPP-4I market, with sitagliptin (Januvia), the former market-leading T2D therapy, undergoing significant market decline with its impending patent expiry in 2027 and the development of sitagliptin generics in the Indian market.

Marketing 52

Marketing Physicians Leads Sales 52

PM360

APRIL 7, 2023

Dan Renick The IRA presents market access teams with a unique opportunity to make recommendations to CMS regarding the evidence and methodology that will be applied in evaluating drugs for upcoming Medicare negotiations that will lead to price adjustments in 2026. Quality and value measurements commonly used outside of the U.S.

Manufacturing 97

Manufacturing Insurance Government Marketing 97

pharmaphorum

DECEMBER 14, 2022

“We are proud to contribute to the Italian and broader global ecosystem supporting the creation and growth of start-ups solving unmet medical needs,” says Filippo Piazza, associate at Angelini Ventures who is leading this strategic partnership. By 2026, Argobio Studio SAS will create and launch five or more biotech companies.

Healthcare 105

Healthcare Healthcare Patients Management 105

Medico Reach

MARCH 24, 2023

It is estimated that global oncology spending will exceed $300 billion by 2026. Proper research and investment in this field can lead to treating the disease efficiently. The body’s response to cancer treatment improves through treatments such as cellular and gene therapies.

Marketing 52

Marketing Medicine Healthcare Healthcare 52

Medico Reach

MARCH 24, 2023

It is estimated that global oncology spending will exceed $300 billion by 2026. Proper research and investment in this field can lead to treating the disease efficiently. The body’s response to cancer treatment improves through treatments such as cellular and gene therapies.

Marketing 52

Marketing Medicine Healthcare Healthcare 52

Pharmaceutical Technology

AUGUST 12, 2022

In the lead-up to a critical meeting that will influence the approval of a new drug for amyotrophic lateral sclerosis (ALS), the US Food and Drug Administration (FDA) has detailed its plans to advance rare neurodegenerative disease research. The Act authorizes the appropriation of $100,000,000 per fiscal year from 2022 to 2026.

FDA 98

FDA Food and Drug Administration Physicians Side effects 98